Skip to main content
Erschienen in: Drugs 5/2005

01.04.2005 | Therapy in Practice

Treatment of Legionnaires’ Disease

verfasst von: Dr Guy W. Amsden

Erschienen in: Drugs | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Legionnaires’ disease is pneumonia, usually caused by Legionella pneumophila, which can range in severity from mild to quite severe. While it is commonly acquired in the community, it can just as easily be acquired nosocomially from water sources that have not been appropriately decontaminated. While historically initial treatment was always with erythromycin, current case series and treatment recommendations suggest that outpatients receive immediate treatment with one of the following antibacterials: azithromycin, erythromycin, clarithromycin, telithromycin, doxycycline or an extended-spectrum fluoroquinolone. If the symptoms are severe enough to warrant hospitalisation then the patient should receive treatment with parenteral azithromycin or extended-spectrum fluoroquinolones followed by step-down to oral formulations to complete the regimens. While a shorter course of 7–10 days for more severe infections may be possible for intravenous/oral azithromycin, other antibacterials should be administered for a total of 10–21 days and started as soon as possible upon presentation to optimise outcomes.
Literatur
1.
Zurück zum Zitat Fraser DW, Tsai TR, Ovenstein W, et al. The field investigation team. Legionnaires’ disease: description of an epidemic of pneumonia. N Engl J Med 1977; 297: 1189–97 Fraser DW, Tsai TR, Ovenstein W, et al. The field investigation team. Legionnaires’ disease: description of an epidemic of pneumonia. N Engl J Med 1977; 297: 1189–97
2.
Zurück zum Zitat Terranova W, Cohen ML, Fraser DW. Outbreak of Legionnaires’ disease diagnosed in 1977. Lancet 1978; 2: 122–4PubMedCrossRef Terranova W, Cohen ML, Fraser DW. Outbreak of Legionnaires’ disease diagnosed in 1977. Lancet 1978; 2: 122–4PubMedCrossRef
3.
Zurück zum Zitat Osterholm MT, Chin TD, Osborne DO, et al. A 1957 outbreak of Legionnaires’ disease associated with a meat packing plant. Am J Epidemiol 1983; 117: 60–7PubMed Osterholm MT, Chin TD, Osborne DO, et al. A 1957 outbreak of Legionnaires’ disease associated with a meat packing plant. Am J Epidemiol 1983; 117: 60–7PubMed
4.
Zurück zum Zitat Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. Am J Med 1996; 101: 508–15PubMedCrossRef Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. Am J Med 1996; 101: 508–15PubMedCrossRef
6.
Zurück zum Zitat Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine (Baltimore) 1990; 69: 307–16 Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine (Baltimore) 1990; 69: 307–16
7.
Zurück zum Zitat Torres A, Sera-Batilles J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312–8PubMedCrossRef Torres A, Sera-Batilles J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312–8PubMedCrossRef
8.
Zurück zum Zitat Yu VL. Legionella pneumophila (Legionnaires’ disease). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia (PA): Churchill Livingstone, 2000: 2424–35 Yu VL. Legionella pneumophila (Legionnaires’ disease). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia (PA): Churchill Livingstone, 2000: 2424–35
9.
Zurück zum Zitat Camerson S, Walker C, Roden D, et al. Epidemiological characteristics of Legionella infection in South Australia: implications for disease control. Aust N Z Med 1991; 21: 65–70CrossRef Camerson S, Walker C, Roden D, et al. Epidemiological characteristics of Legionella infection in South Australia: implications for disease control. Aust N Z Med 1991; 21: 65–70CrossRef
10.
Zurück zum Zitat Muder RR. Other Legionella species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia (PA): Churchill Livingstone, 2000: 2435–41 Muder RR. Other Legionella species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia (PA): Churchill Livingstone, 2000: 2435–41
11.
Zurück zum Zitat Fang GD, Yu VL, Vickers RM. Disease due to Legionellaceae (other than Legionella pneumophila): historical, microbiological, clinical and epidemiological review. Medicine (Baltimore) 1989; 68: 116–39CrossRef Fang GD, Yu VL, Vickers RM. Disease due to Legionellaceae (other than Legionella pneumophila): historical, microbiological, clinical and epidemiological review. Medicine (Baltimore) 1989; 68: 116–39CrossRef
12.
Zurück zum Zitat Best M, Yu VL, Stout J, et al. Legionellaceae in the hospital water supply: epidemiological link with disease and evaluation of a method of control of nosocomial legionnaires’ disease and Pittsburgh pneumonia. Lancet 1983; 2: 307–10PubMedCrossRef Best M, Yu VL, Stout J, et al. Legionellaceae in the hospital water supply: epidemiological link with disease and evaluation of a method of control of nosocomial legionnaires’ disease and Pittsburgh pneumonia. Lancet 1983; 2: 307–10PubMedCrossRef
13.
Zurück zum Zitat Roig J Rello J. Legionnaires’ disease: a rational approach to therapy. J Antimicrob Chemother 2003; 51: 1119–29CrossRef Roig J Rello J. Legionnaires’ disease: a rational approach to therapy. J Antimicrob Chemother 2003; 51: 1119–29CrossRef
14.
Zurück zum Zitat Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 405–33 Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 405–33
15.
Zurück zum Zitat Friedman H, Yamamoto Y, Klein TW. Legionella pneumophila pathogenesis and immunity. Sem Pediatr Infect Dis 2002; 13: 273–9CrossRef Friedman H, Yamamoto Y, Klein TW. Legionella pneumophila pathogenesis and immunity. Sem Pediatr Infect Dis 2002; 13: 273–9CrossRef
16.
Zurück zum Zitat Stout JE, Lin YSE, Goetz AM, et al. Controlling Legionella in hospital water systems: experience with the superheat-and-flush method and copper-silver ionization. Infect Control Hosp Epidemiol 1998; 19: 911–4PubMedCrossRef Stout JE, Lin YSE, Goetz AM, et al. Controlling Legionella in hospital water systems: experience with the superheat-and-flush method and copper-silver ionization. Infect Control Hosp Epidemiol 1998; 19: 911–4PubMedCrossRef
17.
Zurück zum Zitat Dedicoat M, Venkatesan P. The treatment of Legionnaires’ disease. J Antimicrob Chemother 1999; 43: 747–52PubMedCrossRef Dedicoat M, Venkatesan P. The treatment of Legionnaires’ disease. J Antimicrob Chemother 1999; 43: 747–52PubMedCrossRef
18.
Zurück zum Zitat Smith GM Sutherland. Activity of amoxycillin-clavulanic acid against Legionella pneumophila in vitro and in an experimental respiratory infection model. J Hosp Infect 1992; 22 Suppl. A: 61–7PubMedCrossRef Smith GM Sutherland. Activity of amoxycillin-clavulanic acid against Legionella pneumophila in vitro and in an experimental respiratory infection model. J Hosp Infect 1992; 22 Suppl. A: 61–7PubMedCrossRef
19.
Zurück zum Zitat Smith GM, Abbott KH, Sutherland R. Bactericidal effects of coamoxiclav (amoxycillin clavulanic acid) against a Legionella pneumophila pneumonia in the immunocompromised weanling rat. J Antimicrob Chemother 1992; 30: 525–34PubMedCrossRef Smith GM, Abbott KH, Sutherland R. Bactericidal effects of coamoxiclav (amoxycillin clavulanic acid) against a Legionella pneumophila pneumonia in the immunocompromised weanling rat. J Antimicrob Chemother 1992; 30: 525–34PubMedCrossRef
20.
Zurück zum Zitat Stokes DH, Wilkinson MJ, Tyler J, et al. Bactericidal effects of amoxycillin/clavulanic acid against intracellular Legionella pneumophila in tissue culture studies. J Antimicrob Chemother 1989; 23: 547–56PubMedCrossRef Stokes DH, Wilkinson MJ, Tyler J, et al. Bactericidal effects of amoxycillin/clavulanic acid against intracellular Legionella pneumophila in tissue culture studies. J Antimicrob Chemother 1989; 23: 547–56PubMedCrossRef
21.
Zurück zum Zitat Smith GM, Abbott KH, Wilkinson MJ, et al. Bactericidal effects of amoxycillin/clavulanic acid against a Legionella pneumophila pneumonia in the weanling rat. J Antimicrob Chemother 1991; 27: 127–36PubMedCrossRef Smith GM, Abbott KH, Wilkinson MJ, et al. Bactericidal effects of amoxycillin/clavulanic acid against a Legionella pneumophila pneumonia in the weanling rat. J Antimicrob Chemother 1991; 27: 127–36PubMedCrossRef
22.
Zurück zum Zitat Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–10PubMedCrossRef Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–10PubMedCrossRef
23.
Zurück zum Zitat Zimmerman T, Riedel KD, Laufen H, et al. Intravenous toleration of azithromycin in comparison to clarithromycin and erythromycin [abstract no. A82]. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans (LA): American Society for Microbiology, 1996: 16 Zimmerman T, Riedel KD, Laufen H, et al. Intravenous toleration of azithromycin in comparison to clarithromycin and erythromycin [abstract no. A82]. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans (LA): American Society for Microbiology, 1996: 16
24.
Zurück zum Zitat Dournon E, Mayaud C, Wolff M, et al. Comparison of the activity of three antibiotic regimens in severe Legionnaire’s disease. J Antimicrob Chemother 1990; 26 Suppl. B: 129–39PubMedCrossRef Dournon E, Mayaud C, Wolff M, et al. Comparison of the activity of three antibiotic regimens in severe Legionnaire’s disease. J Antimicrob Chemother 1990; 26 Suppl. B: 129–39PubMedCrossRef
25.
Zurück zum Zitat Hubbard RB, Mathur RM, MacFarlane JT. Severe community acquired legionella pneumonia: treatment, complications and outcome. Quart J Med 1993; 86: 327–32PubMed Hubbard RB, Mathur RM, MacFarlane JT. Severe community acquired legionella pneumonia: treatment, complications and outcome. Quart J Med 1993; 86: 327–32PubMed
26.
Zurück zum Zitat Rello J, Bodi M, Mariscal D, et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003; 123: 174–80PubMedCrossRef Rello J, Bodi M, Mariscal D, et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003; 123: 174–80PubMedCrossRef
27.
Zurück zum Zitat Tan MJ, Tan JS, File Jr TM. Legionnaires disease with bacteremic coinfection. Clin Infect Dis 2002; 35: 533–9PubMedCrossRef Tan MJ, Tan JS, File Jr TM. Legionnaires disease with bacteremic coinfection. Clin Infect Dis 2002; 35: 533–9PubMedCrossRef
28.
Zurück zum Zitat Hamedani P, Ali J, Hafeez S, et al. The safety and efficacy of clarithromycin in patients with legionella pneumonia. Chest 1991; 100: 1503–6PubMedCrossRef Hamedani P, Ali J, Hafeez S, et al. The safety and efficacy of clarithromycin in patients with legionella pneumonia. Chest 1991; 100: 1503–6PubMedCrossRef
29.
Zurück zum Zitat Kuzman I, Soldo I, Schönwald S, et al. Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study. Scand J Infect Dis 1995; 27: 503–5PubMedCrossRef Kuzman I, Soldo I, Schönwald S, et al. Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study. Scand J Infect Dis 1995; 27: 503–5PubMedCrossRef
30.
Zurück zum Zitat Plouffe JF, Breiman RF, Fields BS, et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin Infect Dis 2003; 37: 1475–80PubMedCrossRef Plouffe JF, Breiman RF, Fields BS, et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin Infect Dis 2003; 37: 1475–80PubMedCrossRef
31.
Zurück zum Zitat Carbon C, Nusrat R. Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila. Eur J Clin Microbiol Infect Dis 2004; 23: 650–2PubMedCrossRef Carbon C, Nusrat R. Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila. Eur J Clin Microbiol Infect Dis 2004; 23: 650–2PubMedCrossRef
32.
Zurück zum Zitat Santos J, Aguilar L, Garcïa-Méndez E, et al. Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases. J Chemother 2003; 15: 461–5PubMed Santos J, Aguilar L, Garcïa-Méndez E, et al. Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases. J Chemother 2003; 15: 461–5PubMed
33.
Zurück zum Zitat Dorrell L, Fulton B, Ong ELC. Intravenous azithromycin as salvage therapy in a patient with Legionnaire’s disease. Thorax 1994; 49: 620–1PubMedCrossRef Dorrell L, Fulton B, Ong ELC. Intravenous azithromycin as salvage therapy in a patient with Legionnaire’s disease. Thorax 1994; 49: 620–1PubMedCrossRef
34.
Zurück zum Zitat Matute AJ, Schurink CAM, Hoepelman IM. Is a 5 day course of azithromycin enough for infections caused by Legionella pneumophila? J Antimicrob Chemother 2000; 45: 919–31CrossRef Matute AJ, Schurink CAM, Hoepelman IM. Is a 5 day course of azithromycin enough for infections caused by Legionella pneumophila? J Antimicrob Chemother 2000; 45: 919–31CrossRef
35.
Zurück zum Zitat Edelstein PH, Shinzato T, Doyle E, et al. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother. 2001; 45: 2204–9CrossRef Edelstein PH, Shinzato T, Doyle E, et al. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother. 2001; 45: 2204–9CrossRef
36.
Zurück zum Zitat Edelstein PH, Edelstein MAC, Ren J, et al. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1996; 40: 314–9 Edelstein PH, Edelstein MAC, Ren J, et al. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1996; 40: 314–9
37.
Zurück zum Zitat Dubois J, St-Pierre C. In vitro activity of gatifloxacin compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. Diagn Microbiol Infect Dis 1999; 33: 261–5PubMedCrossRef Dubois J, St-Pierre C. In vitro activity of gatifloxacin compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. Diagn Microbiol Infect Dis 1999; 33: 261–5PubMedCrossRef
38.
Zurück zum Zitat Gacouin A, Le Tulzo Y, Lavoue S, et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antibiotic therapy. Intensive Care Med 2002; 28: 686–91PubMedCrossRef Gacouin A, Le Tulzo Y, Lavoue S, et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antibiotic therapy. Intensive Care Med 2002; 28: 686–91PubMedCrossRef
39.
Zurück zum Zitat Lettinga KD, Verbon A, Weverling G-J, et al. Legionnaires’ disease at a Dutch flower show: prognostic factors and impact of therapy. Emerg Infect Dis 2002; 8: 1448–54PubMedCrossRef Lettinga KD, Verbon A, Weverling G-J, et al. Legionnaires’ disease at a Dutch flower show: prognostic factors and impact of therapy. Emerg Infect Dis 2002; 8: 1448–54PubMedCrossRef
40.
Zurück zum Zitat Edelstein PH, Cianciotto NP. Legionella. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia (PA): Churchill Livingstone, 2004: 2711–24 Edelstein PH, Cianciotto NP. Legionella. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia (PA): Churchill Livingstone, 2004: 2711–24
Metadaten
Titel
Treatment of Legionnaires’ Disease
verfasst von
Dr Guy W. Amsden
Publikationsdatum
01.04.2005
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 5/2005
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200565050-00003

Weitere Artikel der Ausgabe 5/2005

Drugs 5/2005 Zur Ausgabe

Adis Drug Evaluation

Gatifloxacin

Leading Article

Contraceptive Vaccines